Inflammatory bowel disease (IBD) is a chronic and life-long disease characterized by
gastrointestinal tract inflammation. It is caused by the interplay of the host's genetic …

The main goals of Ulcerative Colitis (UC) treatment are to both induce and maintain the
clinical and endoscopic remission of disease, reduce the incidence of complications such as …

METHODS: A prospective observational study was conducted on patients with ulcerative
colitis, who started biological therapy with infliximab, adalimumab, golimumab, or …

Background Few data are currently available about SB5 in inflammatory bowel diseases
(IBD). The aim of this study was to assess the effectiveness and safety of SB5 in a cohort of …

Background Infliximab and adalimumab are widely used for the treatment of Crohn's disease
and ulcerative colitis. Aim To compare the long-term efficacy and safety of infliximab and …

Background Loss of response to infliximab or adalimumab in ulcerative colitis occurs
frequently, and dose escalation may aid in regaining clinical benefit. This study aimed to …

Introducción Desde la publicación de la primera edición de la Guía en 2013, se ha
generado mucha información en torno al tratamiento de la colitis ulcerosa, y se han …

Loss of response to antitumor necrosis factor (anti-TNF) therapies in inflammatory bowel
disease occurs in a high proportion of patients. Our aim was to evaluate the loss of response …

The described research focused on the diagnostic usefulness of sulfated
glycosaminoglycans (sGAG), hyaluronan (HA), and extracellular part of syndecan-1 …

Background Italian data currently available in managing ulcerative colitis (UC) and Crohn's
disease (CD) patients with vedolizumab (VDZ) are coming just from secondary and tertiary …